Answers are grounded in this paper and cite their sources.
The Abl tyrosine kinase inhibitor imatinib mesylate (STI-571, Gleevec®, Novartis Pharmaceuticals) is becoming a major agent for the treatment of chronic myelogenous leukaemia (CML). Clinical studies in late chronic phase, accelerated phase and blastic phase of the disease have established the substantial activity of the drug (Savage & Antman, 2002). In all studies, most patients have experienced frequent but mild to moderate side-effects. Haematological toxicity was reported in the advanced phase of the disease and is probably related to the dominant Philadelphia-positive haematopoiesis. The non-haematological adverse events were generally of grade 1 or 2 severity and included superficial oedema, nausea, muscle cramps and skin rashes (Kantarjian et al, 2002). The physiopathology of the skin lesions remains unclear. First reports described skin rashes as hypersensitivity reactions, but some patients have experienced late cutaneous reactions. Furthermore, the incidence of cutaneous reaction to imatinib mesylate appeared to be related to the daily dose (13% for 200–300 mg/d, 16% for 350–500 mg/d and 21% for 600–1000 mg/d), which supports a pharmacodynamic effect of the drug rather than hypersensitivity (Brouard & Saurat, 2001). We report eight cases of photosensitization in CML patients receiving imatinib mesylate therapy. All patients were included in the CSTI571 Novartis Pharmaceuticals clinical trials (six in chronic phase, two in accelerated phase) for which they gave written informed consent. Patient's characteristics are given in Table I. Six patients had achieved a complete haematological response including three with complete cytogenetic response, whereas two remained in chronic phase. At the time of skin reaction, median treatment duration and cumulative dose of imatinib mesylate were 12 months (range 9–20 months) and 156 000 mg (range 120 000–261 000 mg) respectively. The daily dosages were 300 mg (n = 1), 400 mg (n = 6) and 600 mg (n = 1). Sunburn intensities were grade 1 for five patients (painless erythema) and grade 2 for three patients (painful erythema), limited to exposed skin (face and limbs). It is noteworthy that the patients had never experienced any cutaneous reactions since the initiation of imatinib mesylate therapy. None of these subjects had a previous medical history of inherited skin disorders. Anti-nuclear antibodies were negative in the three patients tested. Sun exposure was transient or mild for six patients. Other concomitant skin lesions were observed in three patients and included oedema, urticaria and diffuse hypopigmentation in one ethnically pigmented woman. Cutaneous reaction is the most common adverse effect of imatinib mesylate therapy with a prevalence of 60% for superficial oedema and 32% for skin rashes and related events (Kantarjian et al, 2002). In a single-centre study (Valeyrie et al, 2003) that focused on cutaneous reactions, these rates were significantly higher, with prevalence for oedema and rashes of 65% and 67% respectively. Approximately two-thirds of the patients experienced two or more events (oedema, rash, pruritus) (Valeyrie et al, 2003). However, photosensitization was not reported previously in patients treated with imatinib mesylate. This side-effect was observed only in long-term-treated patients, suggesting that the cumulative dosage represents the unique determinant for photosensitization, whatever the daily dose. Imatinib mesylate is a potent inhibitor of Abl, platelet-derived growth factor (PDGF) and c-kit tyrosine kinases. Mutations of the c-kit gene have been reported in patients with progressive piebaldism, an inherited disorder of melanocyte development (Richards et al, 2001). C-kit-positive melanocyte precursors contribute to melanocyte proliferation and differentiation after ultraviolet (UV) exposure. The reported hypopigmentation in CML patients treated with imatinib mesylate for long periods of time supports the hypothesis that the drug could progressively impair melanogenesis via c-kit tyrosine kinase activity inhibition and thus alter the skin's protection against UV exposure (Raanani et al, 2002). The observations reported here, including excessive response to UV exposure and concomitant hypopigmentation, argue for a tyrosine kinase inhibition-related effect. As UV exposure is directly related to a subsequent risk of skin cancer, we recommend careful sunburn protection in CML patients undergoing long-term therapy with imatinib mesylate.
No takes yet. Share an insight, caveat, or question.
Rousselot et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: